Published on 22/12/2025
Maintaining Legibility in Electronic and Paper Records for Clinical Trials
Why Legibility Matters Under ALCOA Principles
The “L” in ALCOA stands for Legible, a crucial requirement for data reliability in clinical trials. Legibility ensures that anyone reviewing the record—whether a CRA, auditor, or regulator—can easily read and interpret the data as intended. Whether it’s a handwritten note in a subject diary or a clinical assessment in an Electronic Health Record (EHR), if the data cannot be deciphered, it might as well not exist from a compliance perspective.
Regulatory authorities, including the FDA and EMA, have routinely cited trial sites for illegible data during GCP inspections. In a 2022 audit in France, 3 out of 6 patient visit forms were deemed “illegible,” resulting in data exclusion from the statistical analysis set.
To meet GxP standards, sites and sponsors must take proactive steps to maintain legibility across both electronic and paper formats, thereby preserving the reliability and
Legibility in Paper Records: Risks and Best Practices
Despite the growing adoption of electronic documentation, many clinical trial records—especially source documents—remain paper-based. Paper records introduce risks such as poor handwriting, ink fading, and physical damage, all of which compromise legibility.
Best practices for ensuring legible paper records include:
- Use black or blue permanent ink only. Avoid pencils or erasable pens.
- Block letters over cursive writing. Particularly useful in logs and numeric entries.
- No overwriting or correction fluid. Errors must be corrected with a single strike-through, initial, and date.
- Store documents securely. Prevent exposure to moisture, light, and dust.
Consider this legibility checklist for paper source documents:
| Requirement | Compliant Example | Non-Compliant Example |
|---|---|---|
| Writing Style | Printed capital letters | Cursive and smudged handwriting |
| Error Correction | ~130~ 120 mg/dL, initialed and dated | Used white-out over original value |
| Ink Type | Black ballpoint pen | Pencil or highlighter |
A case study from ClinicalStudies.in revealed that a dermatology site failed inspection due to illegible consent date entries, leading to protocol deviation classification. The site had to re-consent 14 participants post-hoc.
Ensuring Legibility in Electronic Health Records (EHRs)
Electronic records offer significant advantages in terms of legibility but are not exempt from risk. Poorly designed user interfaces, truncated fields, and rendering issues can all reduce data clarity. Moreover, scanned PDFs of handwritten notes stored in EHRs must also meet the legibility criteria.
Tips to enhance legibility in electronic systems:
- Use structured data fields instead of free text where possible.
- Choose clear fonts and font sizes (e.g., Arial, Calibri, 11 pt or higher).
- Avoid abbreviations unless universally defined in protocol/SOP.
- Ensure form validation and field expansion to prevent truncated entries.
At pharmaValidation.in, experts recommend EDC vendors conduct annual readability testing and revalidate display formats on mobile and desktop views alike.
Regulatory Expectations and Inspection Trends Related to Legibility
Regulatory agencies worldwide have emphasized that legibility is not just a formality—it’s a legal and scientific necessity. Both ICH E6(R2) and 21 CFR Part 11 state that all clinical trial documentation must be complete, consistent, and legible to enable accurate reconstruction of the trial.
In 2021, the FDA issued a warning letter to a U.S. clinical site conducting a vaccine trial due to illegible subject diaries. Several entries were unreadable, with blurred scanning and smudged ink, leading the sponsor to exclude those subjects from the efficacy analysis set.
Similarly, an inspection by the MHRA (UK) cited multiple CRFs where the printouts from the EHR system were in a font size below 7 pt, making interpretation nearly impossible. These examples highlight how both human error and poor system design can contribute to legibility violations.
Sponsors and CROs are encouraged to:
- Include legibility checks in site monitoring visits.
- Conduct internal audits focusing on documentation readability.
- Define legibility criteria in SOPs and site training programs.
Training Site Staff for Legibility Compliance
The cornerstone of maintaining legible records—whether electronic or paper—is well-trained site personnel. Training should not only cover what “legibility” means but provide visual examples and explain the implications of non-compliance.
Recommended training modules:
- Proper documentation practices (GDP) with emphasis on ALCOA “L”.
- Common legibility errors and how to prevent them.
- Using site-specific documentation templates and checklists.
- Mock audit exercises to identify legibility flaws.
One example from PharmaSOP.in describes a pediatric trial where nurses used bright pink gel pens for dosing logs. The entries faded within 6 months. After retraining and SOP revision, the site adopted standardized black ink and reviewed entries during each monitoring visit.
Conclusion: Legibility Is a Shared Responsibility
Whether a note is handwritten in a subject file or typed into an EHR, it must be legible to serve its purpose in the clinical trial record. Legibility ensures that trial data is trustworthy, reproducible, and inspection-ready.
Sponsors, CROs, and sites must collaborate to enforce documentation standards that uphold ALCOA principles. This includes technology decisions (like user interface design), process controls (like documentation reviews), and people training (like GDP workshops).
To learn more about implementing recordkeeping best practices, visit PharmaGMP.in and review relevant global guidance on documentation quality at WHO Publications.